Immune dysregulation in myelodysplastic syndrome

Immune dysregulation in myelodysplastic syndrome

Myelodysplastic syndrome (MDS) represents one of the most challenging health-related problems in the elderly. Characterized by dysplastic morphology in the bone marrow in association with ineffective hematopoiesis, pathophysiological causes of this disease are diverse including genetic abnormalities...

Full description

Bibliographic Details
Main Authors:	Sugimori, Chiharu, List, Alan F., Epling-Burnette, Pearlie K.
Format:	Online
Language:	English
Published:	PAGEPress Publications 2010
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222262/

Similar Items

Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes
by: Mailloux, Adam W., et al.
Published: (2013)

Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
by: McDaniel, Jessica M., et al.
Published: (2011)

Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes
by: Dong, Wen, et al.
Published: (2016)

Immune Mechanisms in Myelodysplastic Syndrome
by: Glenthøj, Andreas, et al.
Published: (2016)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
by: McGraw, Kathy L., et al.
Published: (2015)

Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency
by: Yang, Lili, et al.
Published: (2012)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
by: Komrokji, R. S., et al.
Published: (2016)

Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome
by: Merrill, Andrea L., et al.
Published: (2011)

Comet assay in myelodysplastic syndromes
by: Teixeira Neto, Paulo Florentino, et al.
Published: (2012)

Molecular Pathogenesis of Myelodysplastic Syndromes
by: Visconte, Valeria, et al.
Published: (2014)

Myelodysplastic syndromes: Classification
by: Hans Peter Horny
Published: (2014-01-01)

Incidence and Burden of the Myelodysplastic Syndromes
by: Cogle, Christopher R.
Published: (2015)

Gingival enlargement in myelodysplastic syndrome
by: George, Navia, et al.
Published: (2015)

Incidence of Myelodysplastic Syndrome in Japan
Published: (2014)

Hereditary Predispositions to Myelodysplastic Syndrome
by: Bannon, Sarah A., et al.
Published: (2016)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
by: McGraw, K L, et al.
Published: (2015)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
by: Giagounidis, Aristoteles, et al.
Published: (2013)

The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes
by: Kittang, Astrid Olsnes, et al.
Published: (2016)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
by: Qin, Taichun, et al.
Published: (2011)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
by: Raj, Kavita, et al.
Published: (2006)

Immunological Derangement in Hypocellular Myelodysplastic Syndromes
by: Serio, B, et al.
Published: (2014)

Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes
by: Kárai, Bettina, et al.
Published: (2013)

Copper deficiency mimicking myelodysplastic syndrome
by: Dalal, Neil, et al.
Published: (2015)

Rare Cytogenetic Abnormalities in Myelodysplastic Syndromes
by: Bacher, Ulrike, et al.
Published: (2015)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
by: McGraw, Kathy L., et al.
Published: (2014)

An Association Between Hypoplastic Myelodysplastic Syndrome and T-Prolymphocytic Leukaemia
by: Arathi, C A, et al.
Published: (2011)

Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations
by: Schubert, Desirée, et al.
Published: (2014)

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
by: Haferlach, T, et al.
Published: (2014)

Bone Marrow Mononuclear Cells Up-Regulate Toll-Like Receptor Expression and Produce Inflammatory Mediators in Response to Cigarette Smoke Extract
by: Zhou, Junmin, et al.
Published: (2011)

The biology of myelodysplastic syndromes: unity despite heterogeneity
by: Raza, Azra, et al.
Published: (2010)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
by: Valent, Peter, et al.
Published: (2010)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
by: Sekeres, M A, et al.
Published: (2014)

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
by: Xu, Feng, et al.
Published: (2014)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
by: Mohd Tohit, Eusni Rahayu, et al.
Published: (2012)

Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes
by: Santini, Valeria, et al.
Published: (2011)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
by: Stintzing, Sebastian, et al.
Published: (2011)

The incidence of myelodysplastic syndromes in Western Greece is increasing
by: Avgerinou, Christina, et al.
Published: (2013)

Discovering Transcription and Splicing Networks in Myelodysplastic Syndromes
by: Wang, Hongyan, et al.
Published: (2013)

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
by: Chesnais, Virginie, et al.
Published: (2012)

Specific Plasma Autoantibody Reactivity in Myelodysplastic Syndromes
by: Mias, George I., et al.
Published: (2013)